Indication Prioritization

Leah Hoffmann

The VP of Global Marketing at a F200 pharma company was reviewing a promising drug about to enter Phase II of R&D. The company’s lean team had already completed a broad indication assessment, but they needed help preparing a more detailed opportunity assessment that leveraged scientific, commercial, and regulatory analysis and could feed late-stage development strategies.

Business Talent Group’s talent was an R&D specialist with biopharma business development experience and deep expertise in the drug’s therapeutic area. Leveraging internal and external research resources, he conducted competitive analyses and financial forecasts and prioritized potential indications by patient group. Then, he delivered strategic recommendations on the top three assets for late-stage clinical development.

 

Previous Article
Integrating Software Systems
Integrating Software Systems

A Big Three consulting firm developed the growth strategy for this F500 B2B company—and identified an acqui...

Next Article
Accelerating an Oncology Drug Launch
Accelerating an Oncology Drug Launch

A F300 pharma company was preparing to launch a new oncology drug. But its understaffed pricing and market ...

×

Talk with BTG to learn more about our on-demand talent.

First Name
Last Name
Company
Country
I would like to receive the latest expert insights and news from Business Talent Group.
By registering, you agree to the processing of your personal data by Business Talent Group as described in the Privacy Statement.
View our Privacy Policy and Cookie Policy
Thank you! We will be in touch shortly.
Error - something went wrong!